Jane Street
IMRX icon

Jane Street’s Immuneering IMRX Stock Holding History

Jane Street’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$145K Buy
29,100
+6,800
+30% +$34.4K ﹤0.01% 10372
2026
Q1 		$118K Sell
22,300
-2,100
-9% -$10.8K ﹤0.01% 10548
2025
Q4 		$161K Buy
+24,400
New +$157K ﹤0.01% 9884

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Jane Street's IMRX Position: Q2 2026 in Review

Jane Street sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 77,414 shares — an estimated $392K sold.

Jane Street first reported a position in IMRX in Q1 2023 and held it in 6 quarters. The position peaked at $671K in Q4 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Jane Street reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 77,414 Immuneering shares in Q2 2026, an estimated $392K.
  • Jane Street first reported a position in Immuneering in Q1 2023 and held it in 6 quarters.
  • Jane Street's Immuneering position peaked at $671K in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.